UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 28, 2018

 

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE		001-35813		98-0376008
(State or Other Jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification No.)

 

142 W. 57th Street, New York, New York		10018
(Address of Principal Executive Offices)		(Zip Code)

 

844-967-2633

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07.  Submission of Matters to a Vote of Security Holders.

 

On August 28, 2018, Oramed Pharmaceuticals Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders. The final voting results are set forth below.

 

Stockholders voted on the following proposals:

 

Proposal No. 1 — Re-election of Directors.

 

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

 

Director Name		For				Against				Abstain				Broker Non-Votes
Miriam Kidron			4,477,104				87,423				17,350				7,359,443
Nadav Kidron			4,496,514				70,234				15,129				7,359,443
Aviad Friedman			4,493,537				70,343				17,997				7,359,443
Xiaopeng Li			4,327,459				232,414				22,004				7,359,443
Kevin Rakin			4,467,661				85,380				28,836				7,359,443
Leonard Sank			4,482,230				71,111				28,536				7,359,443
David Slager			4,492,282				68,511				21,084				7,359,443

 

Proposal No. 2 — Advisory Vote on the Compensation of the Company’s Named Executive Officers.

 

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers listed in the Summary Compensation Table appearing in the Proxy Statement pursuant to Item 402 of Regulation S-K. The votes were as follows:

 

For				Against				Abstain				Broker Non-Votes
	3,661,606				889,122				31,149				7,359,443

 

Proposal No. 3 — Ratification of Auditors.

 

The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the fiscal year ending August 31, 2018. The votes were as follows:

 

For

Against

Abstain

Broker Non-Votes

11,638,832

221,675

80,813

N/A

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	ORAMED PHARMACEUTICALS INC.
	By:	/s/ Nadav Kidron
	Name:	Nadav Kidron
	Title:	President and CEO

 

August 30, 2018

 

 

2